| Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation (NCT01338987) | National Cancer Institute (NCI) | 2011-04-19 |
| A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia (NCT01350947) | University of Utah | 2011-04-01 |
| Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant (NCT01305200) | Children's Oncology Group | 2011-03-01 |
| Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (NCT01484015) | Wake Forest University Health Sciences | 2011-02-01 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (NCT01231919) | National Cancer Institute (NCI) | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts (NCT01241500) | Traws Pharma, Inc. | 2010-11-01 |
| PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias (NCT01169012) | UNC Lineberger Comprehensive Cancer Center | 2010-09-01 |
| Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure (NCT01133886) | King's College London | 2010-09-01 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer (NCT01233921) | Martin, Paul | 2010-09-01 |
| Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm (NCT01101880) | University of Washington | 2010-08-01 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload (NCT01159067) | City of Hope Medical Center | 2010-07-01 |
| Veliparib and Temozolomide in Treating Patients With Acute Leukemia (NCT01139970) | National Cancer Institute (NCI) | 2010-06-04 |
| Lenalidomide in Patients With Chronic Myelomonocytic Leukemia (NCT01368757) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2010-06-01 |
| Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome (NCT00988715) | Fred Hutchinson Cancer Center | 2010-04-21 |
| Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant (NCT01083706) | Fred Hutchinson Cancer Center | 2010-04-01 |
| Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia (NCT01251627) | Fondazione Italiana Sindromi Mielodisplastiche-ETS | 2010-04-01 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (NCT01053494) | Wake Forest University Health Sciences | 2010-04-01 |
| Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (NCT01048034) | Nordic MDS Group | 2010-01-01 |
| A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). (NCT00946647) | Novartis Pharmaceuticals | 2009-12-02 |
| The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia (NCT01010256) | University of Arkansas | 2009-11-01 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01146210) | Children's Oncology Group | 2009-05-01 |
| Registry on Hypomethylating Agents in Myeloid Neoplasms (NCT01595295) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2009-02-09 |
| Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia (NCT00860574) | Fred Hutchinson Cancer Center | 2009-02-01 |
| A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q (NCT00885508) | Groupe Francophone des Myelodysplasies | 2009-02-01 |
| Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (NCT00843882) | National Cancer Institute (NCI) | 2009-01-29 |
| Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders (NCT00856388) | Roswell Park Cancer Institute | 2009-01-14 |
| Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML) (NCT01098084) | Groupe Francophone des Myelodysplasies | 2008-11-01 |
| Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation (NCT00809250) | Dana-Farber Cancer Institute | 2008-11-01 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant (NCT00795769) | Fred Hutchinson Cancer Center | 2008-08-08 |
| A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies (NCT00719836) | S*BIO | 2008-08-01 |
| Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications (NCT00799461) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2008-08-01 |
| Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (NCT00708721) | University of Utah | 2008-03-01 |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders (NCT00588991) | National Cancer Institute (NCI) | 2008-02-04 |
| Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome (NCT00589316) | Fred Hutchinson Cancer Center | 2007-10-05 |
| Aflibercept in Treating Patients With Myelodysplastic Syndromes (NCT00509249) | National Cancer Institute (NCI) | 2007-09-01 |
| Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (NCT00852709) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2007-09-01 |
| Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01093586) | Case Comprehensive Cancer Center | 2007-09-01 |
| MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (NCT00462605) | National Cancer Institute (NCI) | 2007-04-01 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (NCT00489203) | Fred Hutchinson Cancer Center | 2007-04-01 |
| Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (NCT00451048) | National Cancer Institute (NCI) | 2007-02-01 |
| Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT00392353) | National Cancer Institute (NCI) | 2006-11-22 |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis (NCT00387426) | National Cancer Institute (NCI) | 2006-09-01 |
| Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (NCT00313586) | National Cancer Institute (NCI) | 2006-08-01 |
| 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia (NCT00381550) | National Cancer Institute (NCI) | 2006-08-01 |
| Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases (NCT00357708) | National Cancer Institute (NCI) | 2006-06-01 |
| Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (NCT00408681) | Fred Hutchinson Cancer Center | 2006-06-01 |
| Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases (NCT00351975) | National Cancer Institute (NCI) | 2006-06-01 |
| Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (NCT00357305) | National Cancer Institute (NCI) | 2006-05-01 |
| Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders (NCT00397813) | Fred Hutchinson Cancer Center | 2006-01-01 |
| A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT00283114) | Seagen Inc. | 2005-11-01 |
| Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00118352) | Fred Hutchinson Cancer Center | 2005-03-01 |
| Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure (NCT00113321) | M.D. Anderson Cancer Center | 2005-03-01 |
| MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (NCT00101179) | National Cancer Institute (NCI) | 2004-11-03 |
| Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes (NCT00098423) | National Cancer Institute (NCI) | 2004-11-01 |
| XK469R in Treating Patients With Refractory Hematologic Cancer (NCT00095797) | National Cancer Institute (NCI) | 2004-10-01 |
| Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes (NCT00171912) | Novartis Pharmaceuticals | 2004-09-01 |
| Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT00096122) | National Cancer Institute (NCI) | 2004-09-01 |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (NCT00087204) | National Cancer Institute (NCI) | 2004-05-01 |
| CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase (NCT00084916) | National Cancer Institute (NCI) | 2004-04-01 |
| Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia (NCT00079313) | National Heart, Lung, and Blood Institute (NHLBI) | 2004-01-14 |
| Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) (NCT00067808) | M.D. Anderson Cancer Center | 2003-10-01 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant (NCT00078858) | Fred Hutchinson Cancer Center | 2003-09-01 |
| Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT00119366) | Fred Hutchinson Cancer Center | 2003-05-01 |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation (NCT00052520) | Fred Hutchinson Cancer Center | 2002-09-01 |
| Tipifarnib in Treating Patients With Myelodysplastic Syndromes (NCT00005845) | National Cancer Institute (NCI) | 2002-06-01 |
| A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) (NCT00136409) | Dana-Farber Cancer Institute | 2002-05-01 |
| Imatinib Mesylate in Treating Patients With Myelofibrosis (NCT00039416) | National Cancer Institute (NCI) | 2002-04-01 |
| Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer (NCT00027820) | Fred Hutchinson Cancer Center | 2001-08-01 |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction (NCT00025415) | National Cancer Institute (NCI) | 2001-08-01 |
| Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate (NCT00038675) | M.D. Anderson Cancer Center | 2001-06-01 |
| Thalidomide in Treating Patients With Myelodysplastic Syndrome (NCT00015990) | National Cancer Institute (NCI) | 2001-04-01 |
| Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies (NCT00014235) | Fred Hutchinson Cancer Center | 2000-12-01 |
| Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders (NCT02210858) | National Cancer Institute (NCI) | 2000-05-01 |
| Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (NCT00112593) | Fred Hutchinson Cancer Center | 1999-11-01 |
| Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (NCT00008177) | Fred Hutchinson Cancer Center | 1999-07-27 |
| Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies (NCT00038051) | M.D. Anderson Cancer Center | 1999-05-01 |
| Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome (NCT00002798) | National Cancer Institute (NCI) | 1996-08-01 |